Role of nanotechnology in targeted drug delivery and imaging: a concise review
被引:488
作者:
Koo, Otilia M.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL USAUniv Illinois, Dept Biopharmaceut Sci, Chicago, IL USA
Koo, Otilia M.
[1
]
Rubinstein, Israel
论文数: 0引用数: 0
h-index: 0
机构:
Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL USA
Univ Illinois, Dept Med, Chicago, IL USA
Jesse Brown Vet Affairs Med Ctr, Chicago, IL USAUniv Illinois, Dept Biopharmaceut Sci, Chicago, IL USA
Rubinstein, Israel
[1
,2
,3
]
Onyuksel, Hayat
论文数: 0引用数: 0
h-index: 0
机构:
Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL USA
Univ Illinois, Dept Bioengn, Chicago, IL USAUniv Illinois, Dept Biopharmaceut Sci, Chicago, IL USA
Onyuksel, Hayat
[1
,4
]
机构:
[1] Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL USA
[2] Univ Illinois, Dept Med, Chicago, IL USA
[3] Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA
Nanotechnology;
Targeted drug delivery;
Imaging;
Systemic administration;
D O I:
10.1016/j.nano.2005.06.004
中图分类号:
TB3 [工程材料学];
学科分类号:
0805 ;
080502 ;
摘要:
The use of nanotechnology in drug delivery and imaging in vivo is a rapidly expanding field. The emphases of this review are on biophysical attributes of the drug delivery and imaging platforms as well as the biological aspects that enable targeting of these platforms to injured and diseased tissues and cells. The principles of passive and active targeting of nanosized carriers to inflamed and cancerous tissues with increased vascular leakiness, overexpression of specific epitopes, and cellular uptake of these nanoscale systems are discussed. Preparation methods-properties of nanoscale systems including liposomes, micelles, emulsions, nanoparticulates, and dendrimer nanocomposites, and clinical indications are outlined separately for drug delivery and imaging in vivo. Taken together, these relatively new and exciting data indicate that the future of nanomedicine is very promising, and that additional preclinical and clinical studies in relevant animal models and disease states, as well as long-term toxicity studies, should be conducted beyond the bproof-of-conceptQ stage. Large-scale manufacturing and costs of nanomedicines are also important issues to be addressed during development for clinical indications. (C) 2005 Elsevier Inc. All rights reserved.